Harry Welten

Harry has 20 years of international executive experience, more than 11 of which as a CFO in the biotech industry. Prior to joining Cytos, Mr. Welten was CFO at Nitec Pharma AG in Reinach, Switzerland, which merged with US-based Horizon Pharma Inc. and was listed on Nasdaq in 2011. From 2001 to 2009, he was CFO at Arpida AG, Basel, Switzerland, taking the company public in 2005 to the SIX Swiss Exchange and raising more than CHF 250 million in private and public offerings. Prior to joining Arpida, he held various senior management positions at UBS group including Director at UBS Warburg in New York. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He is a member of the Board of Directors of BiognoSYS AG, Horizon Pharma AG, and BioSupport AG, and a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons) from Columbia University, NY, USA.